H. Lang

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

P. Home, M. Landin-Olsson, D. Russell-Jones, 2004, Diabetes care.

Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

S. Skeie, E. Draeger, I. D. De Leeuw, 2005, Diabetes, obesity & metabolism.

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.

A. Roberts, E. Standl, H. Lang, 2004, Diabetes technology & therapeutics.